Eli Lilly and Company $LLY Stock Purchased by Trillium Asset Management LLC

Trillium Asset Management LLC boosted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 1,302.8% in the 3rd quarter, Holdings Channel reports. The firm owned 5,036 shares of the company’s stock after buying an additional 4,677 shares during the quarter. Trillium Asset Management LLC’s holdings in Eli Lilly and Company were worth $5,831,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Coastal Bridge Advisors LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at about $2,959,000. Birinyi Associates Inc. grew its stake in shares of Eli Lilly and Company by 32.6% during the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after acquiring an additional 359 shares in the last quarter. Bernicke Wealth Management Ltd. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at about $5,001,000. Mosaic Family Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after acquiring an additional 1,430 shares during the last quarter. Finally, Canton Hathaway LLC increased its position in shares of Eli Lilly and Company by 160.4% during the third quarter. Canton Hathaway LLC now owns 2,273 shares of the company’s stock worth $2,630,000 after acquiring an additional 1,400 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 1.2%

Shares of LLY traded up $16.77 during midday trading on Friday, hitting $1,444.05. The company had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The company’s 50 day moving average price is $1,242.25 and its 200 day moving average price is $1,110.30. The stock has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the prior year, the business posted $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Insider Buying and Selling

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are a few of the latest headlines about LLY:

  • Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
  • Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study
  • Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. HSBC boosted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, October 30th. Bank of America restated a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. BMO Capital Markets restated an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,416.64.

View Our Latest Research Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.